Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Educational Initiatives for Medical and Pharmacy Students about Drug Promotion: An International Cross-Sectional Survey - EDM Research Series No. 036
(2005; 61 pages) View the PDF document
Table of Contents
View the documentAcknowledgements
Open this folder and view contentsExecutive summary
View the documentIntroduction
View the documentMethods
Open this folder and view contentsResults
View the documentDiscussion
View the documentConclusions
View the documentReferences
View the documentAppendix 1: Sample questionnaire
View the documentAppendix 2: Country breakdown in total


Anonymous. The tightening grip of big pharma. Lancet 2001; 357:1141.

Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73:4-8.

Berings D, Blondeel L, Habraken H. The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. Eur J Clin Pharmacol 1994;46:501-505.

Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing habits. Fam Med. 2002;34:729 -731.

Bombardier C, Laine L, Reicin A, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528.

Caamano F, Figueiras A, Gestal-Otero JJ. Influence of commercial information on prescription quantity in primary care. Eur J Public Health. 2002 Sep; 12(3):187-91.

Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 1996;5:201-6.

Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. Printed educational materials: effects on professional practice and health care outcomes. The Cochrane Database of Systematic Reviews 1997, Issue 2. Art. No.: CD000172. DOI: 10.1002/14651858.CD000172.

Garner SE, Fidan DD, Frankish RR, Maxwell LJ. Rofecoxib for osteoarthritis. The Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD005115. DOI: 10.1002/14651858.CD005115.

Graham DJ. Campen D. Hui R. Spence M. Cheetham C. Levy G. Shoor S. Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005; 365: 475-481.

Haayer F. Rational prescribing and sources of information. Soc Sci Med 1982;16:2017-23.

Harvey K, Black F. (1994) Prescribing rationally, not fashionably (video). WHO Essential Drugs Monitor 1994;17:23.

IMS Health (2002). Total U.S. promotional spending by type. Available at: http://www.democrats.reform.house.gov/Documents/20050505113149-41995.pdf

Jamtvedt G, Young JM, Kristoffersen DT, Thomson O’Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. The Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD000259. DOI: 10.1002/14651858.CD000259.

Shashindran CH, Sethuraman KR. Drug promotion: push, promote or educate? (video). WHO Essential Drugs Monitor 1995;20:24.

Sierles FS, Brodkey AC, Cleary LM, McCurdy FA, Mintz M, Frank J, Lynn DJ, Chao J, Morgenstern BZ, Shore W, Woodard JL. Medical students’ exposure to and attitudes about drug company interactions: a national survey. JAMA 2005; 294:1034-1042.

Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110:551-557.

Suryawati S, Santoso B. Drug advertisements: a critical lesson for Indonesian students. WHO Essential Drugs Monitor 1997; 23: 23.

Thomson O’Brien MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Harvey EL. Educational outreach visits: effects on professional practice and health care outcomes. The Cochrane Database of Systematic Reviews 1997, Issue 4. Art. No.: CD000409. DOI: 10.1002/14651858.CD000409.

Thomson O’Brien MA, Freemantle N, Oxman AD, Wolf F, Davis DA, Herrin J. Continuing education meetings and workshops: effects on professional practice and health care outcomes. The Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD003030. DOI: 10.1002/14651858.CD003030.

Watkins C, Harvey I, Carthy P, Moore L, Robinson E, Brawn R. Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey. Qual Saf Health Care. 2003 Feb; 12(1)29-34.

Waxman, HA. Statement of Rep. Henry A. Waxman for the Hearing, “The Roles of FDA and Pharmaaceutical Companies in Ensuring the Safety of Approved Drugs Like Vioxx.” Congress of the United States. House of Representatives. Committee on Government Reform. Washington D.C.: May 5, 2005. Available at: http://www.democrats.reform.house.gov/Documents/20050505113149-41995.pdf

Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift?. JAMA 2000; 283(3) 373-380.

World Health Organization. Ethical criteria for medicinal drug promotion. Geneva: WHO; 1988.

Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training: a thematic review. J Gen Intern Med 2005; 20: 1-10.


to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017